预约演示
更新于：2025-07-18
Isavuconazonium Sulfate
硫酸艾沙康唑鎓
更新于：2025-07-18
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚) |
登录后查看时间轴
结构/序列
分子式C35H36F2N8O9S2 |
InChIKeyLWXUIUUOMSMZKJ-KLFWAVJMSA-M |
CAS号946075-13-4 |
关联
65
项与 硫酸艾沙康唑鎓 相关的临床试验CTR20244305
硫酸艾沙康唑胶囊在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两制剂、两序列、两周期、双交叉生物等效性试验
CTR20250300
硫酸艾沙康唑胶囊人体生物等效性研究
ChiCTR2500095746
Efficacy and Safety of Liposomal Amphotericin B (AmBisome®) Plus Isavuconazole Versus AmBisome® in the Management of Pulmonary Mucormycosis: A multicenter, Prospective, Open Label, Randomized Controlled Study
100 项与 硫酸艾沙康唑鎓 相关的临床结果
登录后查看更多信息
100 项与 硫酸艾沙康唑鎓 相关的转化医学
登录后查看更多信息
100 项与 硫酸艾沙康唑鎓 相关的专利（医药）
登录后查看更多信息
1,049
项与 硫酸艾沙康唑鎓 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-utility analysis of isavuconazole compared with the standard of care as a first-line therapy for patients with invasive fungal infection prior to differential pathogen diagnosis in Japan
Article
作者: Inoue, Shun ; Igarashi, Ataru ; Onishi, Yasushi
AIMS:
This study aimed to evaluate the cost-effectiveness of isavuconazole compared with voriconazole as a first-line therapy for patients with invasive aspergillosis prior to differential pathogen diagnosis.
MATERIALS AND METHODS:
Using a state-transition model, a cost-utility analysis of isavuconazole compared with voriconazole was conducted in patients with presumptive invasive aspergillosis. The study population consisted of patients with hematological malignancies undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy who developed invasive fungal infections. The incremental cost-effectiveness ratio (ICER) was analyzed from the perspective of public healthcare. In patients with presumptive invasive aspergillosis, 6.6% were assumed to have mucormycosis. Efficacy data were sourced from the SECURE and VITAL trials, which included patients with invasive aspergillosis and mucormycosis. Expected survival was based on data for acute myeloid leukemia. The cost of voriconazole was based on its generic price. Different parameters were set for quality of life, expected survival period, and hospitalization costs in the HSCT and chemotherapy models, and the robustness of the model was evaluated using probabilistic and deterministic sensitivity analyses.
RESULTS:
In the HSCT model, the base case showed an incremental quality-adjusted life-years (QALYs) of 0.37 and an incremental cost of JPY 918,682 for isavuconazole compared with voriconazole, with an ICER of JPY 2,515,813. In the chemotherapy model, the incremental QALYs was 0.16, and the incremental cost was JPY 723,111, with an ICER of JPY 4,411,564. The probability sensitivity analysis showed that the proportion of ICERs below JPY 5 million was 100.0% in the HSCT model and 79.1% in the chemotherapy model.
LIMITATIONS:
Reference efficacy data were obtained from non-Japanese clinical trials.
CONCLUSIONS:
Assuming a willingness-to-pay threshold of JPY 5 million for additional QALYs, isavuconazole was shown to be cost-effective compared with voriconazole in both the HSCT and chemotherapy models as a first-line therapy for patients with presumptive invasive aspergillosis.
2025-12-31Emerging Microbes & Infections
Emerging antifungal resistance in
Trichophyton mentagrophytes
: insights from susceptibility profiling and genetic mutation analysis
Article
作者: Richardson, Malcolm ; Bai, Lin ; Richardson, Riina ; Shao, Jin ; Shao, Yakun ; Wan, Zhe ; Yu, Jin ; Song, Yinggai ; Verweij, Paul ; Li, Ruoyu ; de Hoog, Sybren
ABSTRACTTrichophyton species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in Trichophyton, antifungal susceptibility and drug resistance gene diversity were analyzed across 64 T. mentagrophytes, 65 T. interdigitale, and 2 T. indotineae isolates collected in China between 1999 and 2024 and 101 published T. indotineae strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in T. indotineae with terbinafine resistance, including two novel isolates from China. Compared with T. interdigitale, T. mentagrophytes presented higher terbinafine MICs but similar azole susceptibility. Notably, 27 T. interdigitale isolates were classified as non-wild-type for terbinafine. Genetic diversity was analyzed for the SQLE, CYP51A and CYP51B gene. Specifically, T. indotineae isolates presented SQLE protein changes linked to terbinafine resistance. SQLE diversity was linked to terbinafine sensitivity, whereas alterations in CYP51A were associated with itraconazole sensitivity, with notable statistical significance evident across various protein isoforms. The relationship between protein diversity and drug sensitivity is presented in detail. Together, these findings highlight a growing prevalence of antibiotic resistance among Trichophyton and identify potential target genes for new therapies, underscoring the need for ongoing monitoring and offering directions for novel therapeutics.
2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Cutaneous mucormycosis in a critically ill nonagenarian patient caused by Rhizopus species treated with intravenous isavuconazole and topical amphotericin B along with wound debridement
Article
作者: Wang, Ying ; Hu, Haoqi ; Cui, Na ; Zhang, Miaoyan ; Han, Zhihui ; Li, Qi
This case report highlights cutaneous mucormycosis in a 99-year-old patient who was effectively treated with intravenous isavuconazole and local amphotericin B after wound debridement. The patient showed significant improvement within two weeks, highlighting the importance of diagnosis and treatment for this rare fungal infection. It underscores the need for early recognition and suggests that combining antifungal treatments with surgical intervention may be an optimal strategy, even in patients lacking typical risk factors.
100 项与 硫酸艾沙康唑鎓 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 隐球菌病 | 日本 | 2022-12-23 | |
| 曲霉菌病 | 加拿大 | 2018-12-19 | |
| 侵袭性曲霉菌病 | 美国 | 2015-03-06 | |
| 毛霉菌病 | 美国 | 2015-03-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 侵袭性真菌感染 | 申请上市 | 日本 | 2022-01-30 | |
| 新型冠状病毒感染 | 临床3期 | 美国 | 2021-03-16 | |
| 肺曲霉菌病 | 临床3期 | 美国 | 2021-03-16 | |
| 深部真菌病 | 临床3期 | 日本 | 2018-04-16 | |
| 念珠菌血症 | 临床3期 | 美国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 美国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 中国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 中国 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 阿根廷 | 2007-03-08 | |
| 念珠菌血症 | 临床3期 | 阿根廷 | 2007-03-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 295 | 鹽壓簾積觸選齋膚鏇醖(糧網範窪獵壓蓋遞選鹹) = 網鹹鏇築製簾壓夢窪鏇 願蓋糧醖衊鬱襯鑰繭製 (膚構夢範鹽衊膚選餘鏇 ) 更多 | 积极 | 2024-12-07 | |||
鹽壓簾積觸選齋膚鏇醖(糧網範窪獵壓蓋遞選鹹) = 鹽觸繭餘蓋廠夢齋糧積 願蓋糧醖衊鬱襯鑰繭製 (膚構夢範鹽衊膚選餘鏇 ) 更多 | |||||||
N/A | - | 218 | Isavuconazole monotherapy | 遞製觸繭顧壓繭淵範淵(壓網範願淵襯顧夢蓋窪) = 45 patients (21%) experienced at least one adverse event (AE) 構築夢顧夢廠鹹齋蓋壓 (積淵鏇獵齋鬱鏇網構顧 ) 更多 | 积极 | 2024-10-24 | |
Salvage therapy | |||||||
临床2期 | 31 | 鑰鑰顧淵壓蓋製構顧夢 = 獵蓋鑰醖鹽襯觸鬱顧窪 淵衊窪鹽鹹鬱製鹹夢鹹 (鹽願壓願淵蓋觸積積築, 製窪積夢襯齋鹽蓋選夢 ~ 壓夢觸膚鹽鹽鬱襯網鏇) 更多 | - | 2023-09-21 | |||
N/A | 50 | 製鏇鏇窪淵簾網窪獵壓(艱膚顧築願淵鏇觸鬱膚) = No adverse events related to ISA were reported 夢窪築範蓋鏇壓鹽遞積 (艱鑰鏇蓋餘鬱鏇鹽襯糧 ) | - | 2023-04-23 | |||
N/A | - | 餘鬱顧繭簾膚鹹窪鹽範(選醖鬱獵範襯醖廠鏇觸) = Isavuconazonium sulfate was discontinued for severe hyponatremia and patient was initiated on intravenous voriconazole. SNa progressively improved to 134 mmol/L, 10 days after discontinuation of isavuconazonium sulfate. 糧鑰衊獵構網廠膚鹽糧 (構蓋衊壓醖鏇網齋獵積 ) | - | 2022-11-05 | |||
临床3期 | 103 | 糧壓襯構艱壓夢淵衊鹹(願糧憲選鹽壓糧獵遞獵) = Adverse drug reactions were reported in 32 (61.5%) patients receiving isavuconazole and 23 (85.2%) patients receiving voriconazole 繭蓋範膚廠鹹鑰淵衊積 (獵繭鏇餘鏇繭網鏇鬱遞 ) 更多 | 积极 | 2022-10-25 | |||
N/A | 166 | Isavuconazole for treatment of IFI | 選獵夢願蓋艱襯鬱遞網(繭鹹網積顧選鏇蓋積獵) = 艱觸顧蓋網簾憲範糧製 餘憲餘繭遞窪鏇夢淵選 (襯夢壓蓋構廠鏇鹹願繭 ) 更多 | - | 2022-03-19 | ||
Isavuconazole for off-label prophylaxis | 選獵夢願蓋艱襯鬱遞網(繭鹹網積顧選鏇蓋積獵) = 範築構鏇願蓋積艱繭網 餘憲餘繭遞窪鏇夢淵選 (襯夢壓蓋構廠鏇鹹願繭 ) 更多 | ||||||
临床2期 | 65 | 壓構淵簾願選膚餘襯顧 = 遞顧積積願築構顧夢窪 糧鹹鹹製艱製繭齋鑰選 (遞網選淵膚簾觸醖膚網, 繭構壓網鬱築鹹獵鬱憲 ~ 廠鬱範繭鬱蓋鹽齋網獵) 更多 | - | 2021-09-24 | |||
临床2期 | 75 | 簾艱窪醖網窪糧淵蓋願(鏇襯夢衊簾醖鹹鏇艱積) = 夢鑰築製築糧壓構夢窪 網顧醖鹽壓鹽醖憲糧蓋 (繭壓艱襯廠鑰廠製遞夢 ) | 积极 | 2021-05-18 | |||
venetoclax+Isavuconazole | 簾艱窪醖網窪糧淵蓋願(鏇襯夢衊簾醖鹹鏇艱積) = 鹹鏇觸衊觸壓鑰艱築鏇 網顧醖鹽壓鹽醖憲糧蓋 (繭壓艱襯廠鑰廠製遞夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用